Bradley A. Jacobson

Bradley A. Jacobson

Shareholder

Bradley A. Jacobson advises hedge funds, venture capital funds, private equity funds and investment advisers, as well as public and private companies, in a wide variety of securities, corporate finance, and merger and acquisition transactions. He is experienced in structuring and negotiating public and private offerings (equity and debt, including early and late-stage venture capital transactions and PIPE transactions), mergers, and stock and asset acquisitions. Additionally, Brad advises public and private companies with respect to corporate governance issues, public disclosures and securities law compliance, including proxy statements, registration statements and periodic reports, as well as investors with respect to Section 13 and Section 16 issues.

Concentrations

  • Venture capital and private equity
  • PIPE transactions
  • Public offerings
  • Securities compliance
  • Mergers and acquisitions
  • Corporate governance
Read More +

取扱分野

実績紹介

  • Represented hedge funds, venture capital funds, private equity funds and investment advisers in connection with numerous investments in software, biotechnology, internet, media and entertainment, fintech and other technology companies.
  • Represented public companies in connection with their investment in strategic partners.
  • Represented private companies in connection with fundraising activities.

Representative matters:

  • Represented institutional investor in $530 million Series B financing of Aurora Innovation, Inc., a leading developer of self-driving technology.
  • Represented institutional investor in $300 million Series C financing of Bird Rides, Inc., a leading electric scooter sharing company.
  • Represented institutional investor in $165 million Series D financing of ServiceTitan, Inc., the leading software provider for home services businesses.
  • Represented institutional investor in $400 million Series F financing of Compass, a technology-driven real estate platform.
  • Represented institutional investor in $50 million Series C financing of Allbirds, Inc., a maker of eco-friendly merino wool shoes in casual styles.
  • Represented institutional investor in $185 million Series C financing of Convoy, Inc., a digital freight broker.
  • Represented institutional investor in $427 million Series H financing of Slack Technologies, a leading cloud-based workplace collaboration platform.
  • Represented institutional investor in $125 million Series C financing of Atreca, Inc., a biotechnology company focused on developing novel therapeutics drawn from human immune responses.
  • Represented institutional investor in $90 million Series D financing of PagerDuty, a global leader in digital operations management.
  • Represented institutional investor in $120 million convertible note financing of Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer.
  • Represented institutional investor in $110 million Series E financing of Tempus Labs, Inc., a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data.
  • Represented institutional investor in $550 million Series F financing of Peloton Interactive, Inc., the global fitness technology company.
  • Represented institutional investor in $140 million Series C financing of Gusto, the leading payroll, benefits and HR technology platform for small businesses.
  • Represented institutional investor in $600 million Series I financing of Lyft, Inc., a leading rideshare company.
  • Represented institutional investor in $335 million Series C financing of Lime, a leading scooter and bike sharing company.
  • Represented institutional investor in $125 million Series G financing of Rover, the world’s largest network of pet sitters and dog walkers.
  • Represented institutional investor in $150 million Series G financing of Fuze, Inc., a leading cloud-based communications solution provider for the modern global enterprise.
  • Represented institutional investor in $80 million Series B financing of Fulcrum Therapeutics, Inc., a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases.
  • Represented institutional investor in $100 million Series C financing of Checkr, Inc., a leading background checks platform for the modern economy.
  • Represented institutional investor in $50 million Series C financing of Goop, the modern lifestyle brand founded by Gwyneth Paltrow.
  • Represented institutional investor in $150 million Series C financing of Reddit, Inc., a social news aggregation, web content rating, and discussion website.
  • Represented institutional investor in $500 million Series F financing of Deliveroo, a British online food delivery company.
  • Represented institutional investor in $250 million Series F financing of 23andMe, Inc., a leading personal genetics company.
  • Represented institutional investor in $132 million Series D financing of Outset Medical, Inc., a pioneering medical technology company that develops a hemodialysis system for kidney diseases.
  • Represented institutional investor in $500 million Series G financing of Moderna Therapeutics, a life sciences company pioneering the development of a new class of drugs made of messenger RNA (mRNA).
  • Represented institutional investor in $50 million Series C financing of Principia Biopharma Inc., a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.
  • Represented institutional investor in $65 million Series C financing of AgBiome, which discovers and develops innovative biological and trait products for crop protection.
  • Represented institutional investor in $30 million Series C financing of Framebridge, Inc., an on-line custom framing company.
  • Represented institutional investor in $20 million Series A financing of JetClosing, a leader in digital real estate title and settlement transactions.
  • Represented institutional investor in $45 million Series B financing of Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases.
  • Represented institutional investor in $100 million Series F financing of Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research and development in cancer epigenetics.
  • Represented institutional investor in $100 million Series C financing of Reflexion Medical, Inc., a medical technology company developing the first and only biology-guided radiotherapy system (BgRT) for targeted cancer treatment.
  • Represented institutional investor in $100 million Series D financing of Tempus Labs, Inc., a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data.
  • Represented institutional investor in $80 million Series C financing of Evelo Biosciences, Inc., a biotechnology company pioneering the therapeutic modality of monoclonal microbials.
  • Represented institutional investor in $100 million Series C financing of Rubius Therapeutics, Inc., a company developing Red-Cell Therapeutics as a new treatment modality to address a wide array of indications including cancer, autoimmune disease, rare disease and metabolic disease.
  • Represented issuers and underwriters in connection with more than 20 public offerings of equity and debt securities totaling more than $1.5 billion.
  • Represented public companies, investors and placement agents in numerous PIPE transactions.
  • Represented a public medical device company in connection with a $1.3 billion merger/spin-off transaction.
  • Represented the nation's largest specialty retailer of big and tall men's apparel in the acquisition of a major competitor.
  • Represented a public biotech company in the acquisition of a private vaccine company in a merger.
  • Represented one of the nation's largest banks in connection with the acquisition of the commercial banking business of a competitor.
  • Represented a major office REIT in connection with its $1.2 billion acquisition of the Embarcadero Center in San Francisco.
  • Represented nationally recognized REITs in numerous property acquisitions using equity securities.
  • Represented investors in exit transactions via mergers and acquisitions.

受賞歴・所属団体

  • Listed, Acritas Stars™ Independently Rated Lawyers, “Star Lawyers,” 2019
  • Team Member, Corporate Board Member magazine and FTI Consulting Inc., one of "America’s Best Corporate Law Firms," 13th Annual Legal Industry Study, 2013
  • Listed, Super Lawyers magazine, Super Lawyers of Massachusetts, "Rising Star," 2005-2006
  • Member, Boston Bar Association
  • Member, Massachusetts Bar Association

学歴・資格・言語

学歴
  • J.D., magna cum laude, Boston College Law School, 1995
    • Topics Editor, Boston College Law Review
  • B.S., Finance, magna cum laude, Boston College, 1989
    • Carroll School of Management
弁護士資格
  • Massachusetts
言語